Newly developed retatrutide, a combined-action drug targeting equally GLP-1 and GIP receptors, is sparking considerable buzz within the medical community. Preliminary clinical trials have revealed substantial reductions in overall size and gains in physiological markers for patients with excess weight . Researchers believe this unique approach has